CoChat

Glial cells and adaptive immunity in frontotemporal dementia with tau pathology

Hartnell, Iain J, Blum, David, Nicoll, James A R, Dorothee, Guillaume, Boche, Delphine · 2021 · Brain
Cited by 42

The DOI matches its Crossref record; 100 of the 100 references it cites were found in a registry or an index.

Abstract

Neuroinflammation is involved in the aetiology of many neurodegenerative disorders including Alzheimer’s disease, Parkinson’s disease and motor neuron disease. Whether neuroinflammation also plays an important role in the pathophysiology of frontotemporal dementia is less well known. Frontotemporal dementia is a heterogeneous classification that covers many subtypes, with the main pathology known as frontotemporal lobar degeneration. The disease can be categorized with respect to the identity of the protein that causes the frontotemporal lobar degeneration in the brain. The most common subgroup describes diseases caused by frontotemporal lobar degeneration associated with tau aggregation, also known as primary tauopathies. Evidence suggests that neuroinflammation may play a role in primary tauopathies with genome-wide association studies finding enrichment of genetic variants associated with specific inflammation-related gene loci. These loci are related to both the innate immune system, including brain resident microglia, and the adaptive immune system through possible peripheral T-cell involvement. This review discusses the genetic evidence and relates it to findings in animal models expressing pathogenic tau as well as to post-mortem and PET studies in human disease. Across experimental paradigms, there seems to be a consensus regarding the involvement of innate immunity in primary tauopathies, with increased microglia and astrocyte density and/or activation, as well as increases in pro-inflammatory markers. Whilst it is less clear as to whether inflammation precedes tau aggregation or vice versa; there is strong evidence to support a microglial contribution to the propagation of hyperphosphorylated in tau frontotemporal lobar degeneration associated with tau aggregation. Experimental evidence—albeit limited—also corroborates genetic data pointing to the involvement of cellular adaptive immunity in primary tauopathies. However, it is still unclear whether brain recruitment of peripheral immune cells is an aberrant result of pathological changes or a physiological aspect of the neuroinflammatory response to the tau pathology.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/brain/awaa457

Cites

100 of 100 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 129

  1. Abu-Rumeileh, 2019, CSF biomarkers of neuroinflammation in distinct forms and subtypes of neurodegenerative dementia, Alzheimers Res Ther, 12, 2, 10.1186/s13195-019-0562-4 · DOI · Paper page
  2. Ahmed, 2015, Rescue of impaired late-phase long-term depression in a tau transgenic mouse model, Neurobiol Aging, 36, 730, 10.1016/j.neurobiolaging.2014.09.015 · DOI
  3. Ajmone-Cat, 2019, Increased FUS levels in astrocytes leads to astrocyte and microglia activation and neuronal death, Sci Rep, 9, 4572, 10.1038/s41598-019-41040-4 · DOI · Paper page
  4. Allen, 2002, Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein, J Neurosci, 22, 9340, 10.1523/JNEUROSCI.22-21-09340.2002 · DOI · Paper page
  5. Amin, 2017, What do we know about the inflammasome in humans?, Brain Pathol, 27, 192, 10.1111/bpa.12479 · DOI
  6. Andreasson, 2001, Age-dependent cognitive deficits and neuronal apoptosis in cyclooxygenase-2 transgenic mice, J Neurosci, 21, 8198, 10.1523/JNEUROSCI.21-20-08198.2001 · DOI · Paper page
  7. Babcock, 2003, Chemokine expression by glial cells directs leukocytes to sites of axonal injury in the CNS, J Neurosci, 23, 7922, 10.1523/JNEUROSCI.23-21-07922.2003 · DOI · Paper page
  8. Barker, 2002, Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank, Alzheimer Dis Assoc Disord, 16, 203, 10.1097/00002093-200210000-00001 · DOI · Paper page
  9. Bellucci, 2004, Induction of inflammatory mediators and microglial activation in mice transgenic for mutant human P301S tau protein, Am J Pathol, 165, 1643, 10.1016/S0002-9440(10)63421-9 · DOI · Paper page
  10. Beyer, 2018, Translocator protein 18kDa (TSPO) expression in patients with clinically diagnosed progressive supranuclear palsy, J Nucl Med, 59, 1700
  11. Bigio, 1999, Progressive supranuclear palsy with dementia: cortical pathology, J Neuropathol Exp Neurol, 58, 359, 10.1097/00005072-199904000-00006 · DOI · Paper page
  12. Boccardi, 2004, APOE and modulation of Alzheimer's and frontotemporal dementia, Neurosci Lett, 356, 167, 10.1016/j.neulet.2003.11.042 · DOI · Paper page
  13. Boche, 2013, Review: activation patterns of microglia and their identification in the human brain, Neuropathol Appl Neurobiol, 39, 3, 10.1111/nan.12011 · DOI · Paper page
  14. Bonham, 2018, CXCR4 involvement in neurodegenerative diseases, Transl Psychiatry, 8, 73, 10.1038/s41398-017-0049-7 · DOI · Paper page
  15. Bouwmeester, 2004, A physical and functional map of the human TNF-alpha/NF-kappa B signal transduction pathway, Nat Cell Biol, 6, 97, 10.1038/ncb1086 · DOI · Paper page
  16. Boxer, 2013, Frontotemporal degeneration, the next therapeutic frontier: molecules and animal models for frontotemporal degeneration drug development, Alzheimers Dement, 9, 176, 10.1016/j.jalz.2012.03.002 · DOI · Paper page
  17. Broce, 2018, Immune-related genetic enrichment in frontotemporal dementia: an analysis of genome-wide association studies, PLoS Med, 15, e1002487, 10.1371/journal.pmed.1002487 · DOI · Paper page
  18. Brodie, 1998, Functional IL-4 receptors on mouse astrocytes: IL-4 inhibits astrocyte activation and induces NGF secretion, J Neuroimmunol, 81, 20, 10.1016/S0165-5728(97)00154-9 · DOI
  19. Burnouf, 2013, NMDA receptor dysfunction contributes to impaired brain-derived neurotrophic factor-induced facilitation of hippocampal synaptic transmission in a Tau transgenic model, Aging Cell, 12, 11, 10.1111/acel.12018 · DOI · Paper page
  20. Carvalho, 2019, Exacerbation of C1q dysregulation, synaptic loss and memory deficits in tau pathology linked to neuronal adenosine A2A receptor, Brain, 142, 3636, 10.1093/brain/awz288 · DOI · Paper page
  21. Chouery, 2008, Mutations in TREM2 lead to pure early-onset dementia without bone cysts, Hum Mutat, 29, E194, 10.1002/humu.20836 · DOI · Paper page
  22. Corder, 1993, Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families, Science, 261, 921, 10.1126/science.8346443 · DOI · Paper page
  23. Cuyvers, 2014, Investigating the role of rare heterozygous TREM2 variants in Alzheimer's disease and frontotemporal dementia, Neurobiol Aging, 35, 726.e11, 10.1016/j.neurobiolaging.2013.09.009 · DOI · Paper page
  24. Dachsel, 2007, Lrrk2 G2019S substitution in frontotemporal lobar degeneration with ubiquitin-immunoreactive neuronal inclusions, Acta Neuropathol, 113, 601, 10.1007/s00401-006-0178-1 · DOI
  25. Dale, 2017, Inflammatory pathology and rapidly progressive dementia contribute to the classic PSP phenotype (P4.014), Neurology, 88, P4, 10.1212/WNL.88.16_supplement.P4.014 · doi:10.1212/wnl.88.16_supplement.p4.014
  26. Darwent, 2017, Mutations in TYROBP are not a common cause of dementia in a Turkish cohort, Neurobiol Aging, 58, 240.e1, 10.1016/j.neurobiolaging.2017.06.019 · DOI
  27. Das, 2020, Phagocytosis of full-length Tau oligomers by Actin-remodeling of activated microglia, J Neuroinflammation, 17, 10, 10.1186/s12974-019-1694-y · DOI · Paper page
  28. Dennis, 2016, Human adult neurogenesis across the ages: an immunohistochemical study, Neuropathol Appl Neurobiol, 42, 621, 10.1111/nan.12337 · DOI · Paper page
  29. Espeseth, 2008, Accelerated age-related cortical thinning in healthy carriers of apolipoprotein E epsilon 4, Neurobiol Aging, 29, 329, 10.1016/j.neurobiolaging.2006.10.030 · DOI
  30. Fahrenhold, 2018, TREM2 expression in the human brain: a marker of monocyte recruitment?, Brain Pathol, 28, 595, 10.1111/bpa.12564 · DOI · Paper page
  31. Farrer, 1997, Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium, JAMA, 278, 1349, 10.1001/jama.1997.03550160069041 · DOI · Paper page
  32. Fennema-Notestine, 2011, Presence of ApoE ε4 allele associated with thinner frontal cortex in middle age, J Alzheimers Dis, 26, 49, 10.3233/JAD-2011-0002 · DOI · Paper page
  33. Ferrari, 2016, Frontotemporal dementia: insights into the biological underpinnings of disease through gene co-expression network analysis, Mol Neurodegener, 11, 21, 10.1186/s13024-016-0085-4 · DOI · Paper page
  34. Ferrari, 2017, Genetic architecture of sporadic frontotemporal dementia and overlap with Alzheimer's and Parkinson's diseases, J Neurol Neurosurg Psychiatry, 88, 152, 10.1136/jnnp-2016-314411 · DOI · Paper page
  35. Franco-Bocanegra, 2018, Innate immunity in Alzheimer's disease: the relevance of animal models?, J Neural Transm, 125, 827, 10.1007/s00702-017-1729-4 · DOI · Paper page
  36. Galimberti, 2015, Inflammatory molecules in Frontotemporal Dementia: cerebrospinal fluid signature of progranulin mutation carriers, Brain Behav Immun, 49, 182, 10.1016/j.bbi.2015.05.006 · DOI
  37. Gendreau, 2013, Tangles, toxicity, and tau secretion in ad - new approaches to a vexing problem, Front Neurol, 4, 160, 10.3389/fneur.2013.00160 · DOI · Paper page
  38. Geschwind, 1998, The apolipoprotein E epsilon4 allele is not a significant risk factor for frontotemporal dementia, Ann Neurol, 44, 134, 10.1002/ana.410440122 · DOI · Paper page
  39. Ghetti, 2015, Invited review: frontotemporal dementia caused by microtubule-associated protein tau gene (MAPT) mutations: a chameleon for neuropathology and neuroimaging, Neuropathol Appl Neurobiol, 41, 24, 10.1111/nan.12213 · DOI · Paper page
  40. Ginhoux, 2010, Fate mapping analysis reveals that adult microglia derive from primitive macrophages, Science, 330, 841, 10.1126/science.1194637 · DOI · Paper page
  41. Gorno-Tempini, 2011, Classification of primary progressive aphasia and its variants, Neurology, 76, 1006, 10.1212/WNL.0b013e31821103e6 · DOI · Paper page
  42. Hall, 2018, Cerebrospinal fluid concentrations of inflammatory markers in Parkinson's disease and atypical parkinsonian disorders, Sci Rep, 8, 13276, 10.1038/s41598-018-31517-z · DOI · Paper page
  43. Hampton, 2010, Cell-mediated neuroprotection in a mouse model of human tauopathy, J Neurosci, 30, 9973, 10.1523/JNEUROSCI.0834-10.2010 · DOI · Paper page
  44. Hardy, 2014, Motor neuron disease and frontotemporal dementia: sometimes related, sometimes not, Exp Neurol, 262, 75, 10.1016/j.expneurol.2013.11.006 · DOI
  45. Harvey, 2003, The prevalence and causes of dementia in people under the age of 65 years, J Neurol Neurosurg Psychiatry, 74, 1206, 10.1136/jnnp.74.9.1206 · DOI · Paper page
  46. Hauw, 1994, Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy), Neurology, 44, 2015, 10.1212/WNL.44.11.2015 · DOI · Paper page
  47. Helboe, 2017, Early depletion of CA1 neurons and late neurodegeneration in a mouse tauopathy model, Brain Res, 1665, 22, 10.1016/j.brainres.2017.04.002 · DOI
  48. Henderson, 2019, Alzheimer’s disease tau is a prominent pathology in LRRK2 Parkinson’s disease, Acta Neuropathol Commun, 7, 183, 10.1186/s40478-019-0836-x · DOI · Paper page
  49. Henstridge, 2019, Glial contribution to excitatory and inhibitory synapse loss in neurodegeneration, Front Cell Neurosci, 13, 63, 10.3389/fncel.2019.00063 · DOI · Paper page
  50. Herx, 2001, Interleukin-1β is required for the early evolution of reactive astrogliosis following CNS lesion, J Neuropathol Exp Neurol, 60, 961, 10.1093/jnen/60.10.961 · DOI · Paper page
  51. Hoffmann, 2013, Impaired plasticity of cortical dendritic spines in P301S tau transgenic mice, Acta Neuropathol Commun, 1, 82, 10.1186/2051-5960-1-82 · DOI · Paper page
  52. Hogan, 2016, The prevalence and incidence of frontotemporal dementia: a systematic review, Can J Neurol Sci, 43, S96, 10.1017/cjn.2016.25 · DOI · Paper page
  53. Hollister, 1997, Neuronal expression of class II major histocompatibility complex (HLA-DR) in 2 cases of Pick disease, Arch Neurol, 54, 243, 10.1001/archneur.1997.00550150011008 · DOI
  54. Huang, 2011, FUS transgenic rats develop the phenotypes of amyotrophic lateral sclerosis and frontotemporal lobar degeneration, PLoS Genet, 7, e1002011, 10.1371/journal.pgen.1002011 · DOI · Paper page
  55. Hudson, 2005, Astrocytes and microglia differentially regulate trafficking of lymphocyte subsets across brain endothelial cells, Brain Res, 1058, 148, 10.1016/j.brainres.2005.07.071 · DOI
  56. Inbar, 2010, Possible role of tau in mediating pathological effects of apoE4 in vivo prior to and following activation of the amyloid cascade, Neurodegenerative Dis, 7, 16, 10.1159/000283477 · DOI · Paper page
  57. Jackson, 2017, Altered Synapse Stability in the Early Stages of Tauopathy, Cell Rep, 18, 3063, 10.1016/j.celrep.2017.03.013 · DOI · Paper page
  58. Jha, 2018, Functional dissection of astrocyte-secreted proteins: Implications in brain health and diseases, Prog Neurobiol, 162, 37, 10.1016/j.pneurobio.2017.12.003 · DOI
  59. Jiang, 2018, TREM2 ameliorates neuronal tau pathology through suppression of microglial inflammatory response, Inflammation, 41, 811, 10.1007/s10753-018-0735-5 · DOI
  60. Josephs, 2011, Neuropathological background of phenotypical variability in frontotemporal dementia, Acta Neuropathol, 122, 137, 10.1007/s00401-011-0839-6 · DOI · Paper page
  61. Josephs, 2006, Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP, Neurology, 66, 41, 10.1212/01.wnl.0000191307.69661.c3 · DOI · Paper page
  62. Kaneko, 2010, Nasu-Hakola disease: the first case reported by Nasu and review, Neuropathology, 30, 70, 10.1111/j.1440-1789.2010.01127.x · DOI · Paper page
  63. Karch, 2012, Extracellular Tau levels are influenced by variability in Tau that is associated with tauopathies, J Biol Chem, 287, 42751, 10.1074/jbc.M112.380642 · DOI · Paper page
  64. Kida, 1992, Immunohistochemical study of a case with progressive supranuclear palsy without ophthalmoplegia, Acta Neuropathol, 83, 328, 10.1007/BF00296797 · DOI
  65. Kim, 2019, Neuroinflammation in frontotemporal lobar degeneration revealed by 11C-PBR28 PET, Ann Clin Transl Neurol, 6, 1327, 10.1002/acn3.50802 · DOI
  66. Knopman, 2005, Antemortem diagnosis of frontotemporal lobar degeneration, Ann Neurol, 57, 480, 10.1002/ana.20425 · DOI · Paper page
  67. Kobayashi, 1999, KP1 expression of ghost Pick bodies, amyloid P-positive astrocytes and selective nigral degeneration in early onset Picks disease, Clin Neuropathol, 18, 240
  68. Kober, 2016, Neurodegenerative disease mutations in TREM2 reveal a functional surface and distinct loss-of-function mechanisms, eLife, 5, e20391, 10.7554/eLife.20391 · DOI · Paper page
  69. Komori, 1998, Inducible nitric oxide synthase (iNOS)-like immunoreactivity in argyrophilic, tau-positive astrocytes in progressive supranuclear palsy, Acta Neuropathol, 95, 338, 10.1007/s004010050808 · DOI
  70. Kosik, 1989, Developmentally regulated expression of specific tau sequences, Neuron, 2, 1389, 10.1016/0896-6273(89)90077-9 · DOI · Paper page
  71. Krabbe, 2017, Microglial NFkappaB-TNFalpha hyperactivation induces obsessive-compulsive behavior in mouse models of progranulin-deficient frontotemporal dementia, 5029
  72. Lattante, 2013, TREM2 mutations are rare in a French cohort of patients with frontotemporal dementia, Neurobiol Aging, 34, 2443.e1, 10.1016/j.neurobiolaging.2013.04.030 · DOI
  73. Laurent, 2017, Hippocampal T cell infiltration promotes neuroinflammation and cognitive decline in a mouse model of tauopathy, Brain, 140, 184, 10.1093/brain/aww270 · DOI · Paper page
  74. Laurent, 2014, Beneficial effects of caffeine in a transgenic model of Alzheimer's disease-like tau pathology, Neurobiol Aging, 35, 2079, 10.1016/j.neurobiolaging.2014.03.027 · DOI · Paper page
  75. Lavisse, 2012, Reactive astrocytes overexpress TSPO and are detected by TSPO positron emission tomography imaging, J Neurosci, 32, 10809, 10.1523/JNEUROSCI.1487-12.2012 · DOI · Paper page
  76. Lemstra, 2007, Microglia activation in sepsis: a case-control study, J Neuroinflammation, 4, 4, 10.1186/1742-2094-4-4 · DOI
  77. Ling, 2013, TDP-43 pathology in a patient carrying G2019S LRRK2 mutation and a novel p.Q124E MAPT, Neurobiol Aging, 34, 2889.e5, 10.1016/j.neurobiolaging.2013.04.011 · DOI · Paper page
  78. Lively, 2018, Microglia responses to pro-inflammatory stimuli (LPS, IFNγ+TNFα) and reprogramming by resolving cytokines (IL-4, IL-10), Front Cell Neurosci, 12, 215, 10.3389/fncel.2018.00215 · DOI · Paper page
  79. Lladó, 2008, Clinicopathological and genetic correlates of frontotemporal lobar degeneration and corticobasal degeneration, J Neurol, 255, 488, 10.1007/s00415-008-0565-8 · DOI
  80. Lobo-Silva, 2016, Balancing the immune response in the brain: IL-10 and its regulation, J Neuroinflammation, 13, 297, 10.1186/s12974-016-0763-8 · DOI · Paper page
  81. Mederos, 2018, Astrocyte-neuron networks: a multilane highway of signaling for homeostatic brain function, Front Synaptic Neurosci, 10, 45, 10.3389/fnsyn.2018.00045 · DOI · Paper page
  82. Merlini, 2018, Extravascular CD3+ T cells in brains of Alzheimer disease patients correlate with tau but not with amyloid pathology: an immunohistochemical study, Neurodegener Dis, 18, 49, 10.1159/000486200 · DOI · Paper page
  83. Mishra, 2017, Gene-based association studies report genetic links for clinical subtypes of frontotemporal dementia, Brain, 140, 1437, 10.1093/brain/awx066 · DOI · Paper page
  84. Mishra, 2016, Astrocytes mediate neurovascular signaling to capillary pericytes but not to arterioles, Nat Neurosci, 19, 1619, 10.1038/nn.4428 · DOI · Paper page
  85. Mori, 2016, Neuroimmunology of the Interleukins 13 and 4, Brain Sci, 6, 18, 10.3390/brainsci6020018 · DOI · Paper page
  86. Neher, 2019, Priming microglia for innate immune memory in the brain, Trends Immunol, 40, 358, 10.1016/j.it.2019.02.001 · DOI · Paper page
  87. Nguyen, 2018, G2019S LRRK2 enhances the neuronal transmission of tau in the mouse brain, Hum Mol Genet, 27, 120, 10.1093/hmg/ddx389 · DOI · Paper page
  88. Nilsson, 2014, Age-related incidence and family history in frontotemporal dementia: data from the Swedish Dementia Registry, PLoS One, 9, e94901, 10.1371/journal.pone.0094901 · DOI · Paper page
  89. Nimmerjahn, 2005, Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo, Science, 308, 1314, 10.1126/science.1110647 · DOI · Paper page
  90. Penkowa, 1999, Strongly compromised inflammatory response to brain injury in interleukin-6-deficient mice, Glia, 25, 343, 10.1002/(SICI)1098-1136(19990215)25:4<343::AID-GLIA4>3.0.CO;2-V · DOI · Paper page
  91. Persidsky, 1999, Microglial and astrocyte chemokines regulate monocyte migration through the blood-brain barrier in human immunodeficiency virus-1 encephalitis, Am J Pathol, 155, 1599, 10.1016/S0002-9440(10)65476-4 · DOI · Paper page
  92. Prebil, 2011, Dynamic monitoring of cytosolic glucose in single astrocytes, Glia, 59, 903, 10.1002/glia.21161 · DOI · Paper page
  93. Rabinovici, 2010, Frontotemporal lobar degeneration: epidemiology, pathophysiology, diagnosis and management, CNS Drugs, 24, 375, 10.2165/11533100-000000000-00000 · DOI · Paper page
  94. Rakic, 2018, Systemic infection modifies the neuroinflammatory response in late stage Alzheimer's disease, Acta Neuropathol Commun, 6, 88, 10.1186/s40478-018-0592-3 · DOI · Paper page
  95. Rascovsky, 2011, Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia, Brain, 134, 2456, 10.1093/brain/awr179 · DOI · Paper page
  96. Rascovsky, 2005, Rate of progression differs in frontotemporal dementia and Alzheimer disease, Neurology, 65, 397, 10.1212/01.wnl.0000171343.43314.6e · DOI · Paper page
  97. Reu, 2017, The lifespan and turnover of microglia in the human brain, Cell Rep, 20, 779, 10.1016/j.celrep.2017.07.004 · DOI · Paper page
  98. Romero-Molina, 2018, Distinct microglial responses in two transgenic murine models of TAU pathology, Front Cell Neurosci, 12, 421, 10.3389/fncel.2018.00421 · DOI · Paper page
  99. Rubino, 2013, Apolipoprotein E polymorphisms in frontotemporal lobar degeneration: a meta-analysis, Alzheimers Dement, 9, 706, 10.1016/j.jalz.2012.10.013 · DOI · Paper page
  100. Ruiz, 2014, Assessing the role of the TREM2 p.R47H variant as a risk factor for Alzheimer's disease and frontotemporal dementia, Neurobiol Aging, 35, 444.e1-4, 10.1016/j.neurobiolaging.2013.08.011 · DOI · Paper page
  101. Salamanca, 2019, MIC-MAC: An automated pipeline for high-throughput characterization and classification of three-dimensional microglia morphologies in mouse and human postmortem brain samples, Glia, 67, 1496, 10.1002/glia.23623 · DOI · Paper page
  102. Sanchez-Contreras, 2017, Study of LRRK2 variation in tauopathy: progressive supranuclear palsy and corticobasal degeneration, Mov Disord, 32, 115, 10.1002/mds.26815 · DOI · Paper page
  103. Santacruz, 2005, Tau suppression in a neurodegenerative mouse model improves memory function, Science, 309, 476, 10.1126/science.1113694 · DOI · Paper page
  104. Santos, 2014, Reduced frequency of T lymphocytes expressing CTLA-4 in frontotemporal dementia compared to Alzheimer's disease, Progress Neuropsychopharmacol Biol Psychiatry, 48, 1, 10.1016/j.pnpbp.2013.06.019 · DOI
  105. Sasaki, 2008, Microglial activation in brain lesions with tau deposits: comparison of human tauopathies and tau transgenic mice TgTauP301L, Brain Res, 1214, 159, 10.1016/j.brainres.2008.02.084 · DOI
  106. Satoh, 2018, Alzheimer's disease pathology in Nasu-Hakola disease brains, Intractable Rare Dis Res, 7, 32, 10.5582/irdr.2017.01088 · DOI · Paper page
  107. Schindowski, 2006, Alzheimer's disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits, Am J Pathol, 169, 599, 10.2353/ajpath.2006.060002 · DOI · Paper page
  108. Schofield, 2003, Severity of gliosis in Pick’s disease and frontotemporal lobar degeneration: tau-positive glia differentiate these disorders, Brain, 126, 827, 10.1093/brain/awg085 · DOI · Paper page
  109. Shi, 2005, Histopathological changes underlying frontotemporal lobar degeneration with clinicopathological correlation, Acta Neuropathol, 110, 501, 10.1007/s00401-005-1079-4 · DOI
  110. Shi, 2019, Microglia drive APOE-dependent neurodegeneration in a tauopathy mouse model, J Exp Med, 216, 2546, 10.1084/jem.20190980 · DOI · Paper page
  111. Shiarli, 2006, Comparison of extent of tau pathology in patients with frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17), frontotemporal lobar degeneration with Pick bodies and early onset Alzheimer's disease, Neuropathol Appl Neurobiol, 32, 374, 10.1111/j.1365-2990.2006.00736.x · DOI · Paper page
  112. Sidoryk-Wegrzynowicz, 2017, Astrocytes in mouse models of tauopathies acquire early deficits and lose neurosupportive functions, Acta Neuropathol Commun, 5, 89, 10.1186/s40478-017-0478-9 · DOI · Paper page
  113. Sloan, 2013, Glia as primary drivers of neuropathology in TDP-43 proteinopathies, Proc Natl Acad Sci USA, 110, 4439, 10.1073/pnas.1301608110 · DOI
  114. Snowden, 2011, The clinical diagnosis of early-onset dementias: diagnostic accuracy and clinicopathological relationships, Brain, 134, 2478, 10.1093/brain/awr189 · DOI · Paper page
  115. Sokolowski, 2011, Phagocytic clearance in neurodegeneration, Am J Pathol, 178, 1416, 10.1016/j.ajpath.2010.12.051 · DOI
  116. Stamatovic, 2008, Brain endothelial cell-cell junctions: how to "open" the blood brain barrier, Curr Neuropharmacol, 6, 179, 10.2174/157015908785777210 · DOI · Paper page
  117. Stancu, 2019, Aggregated Tau activates NLRP3-ASC inflammasome exacerbating exogenously seeded and non-exogenously seeded Tau pathology in vivo, Acta Neuropathol, 137, 599, 10.1007/s00401-018-01957-y · DOI · Paper page
  118. Starhof, 2018, Cerebrospinal fluid pro-inflammatory cytokines differentiate parkinsonian syndromes, J Neuroinflammation, 15, 305, 10.1186/s12974-018-1339-6 · DOI · Paper page
  119. Tacik, 2017, Clinicopathologic heterogeneity in frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17) due to microtubule-associated protein tau (MAPT) p.P301L mutation, including a patient with globular glial tauopathy, Neuropathol Appl Neurobiol, 43, 200, 10.1111/nan.12367 · DOI · Paper page
  120. Taskesen, 2017, Susceptible genes and disease mechanisms identified in frontotemporal dementia and frontotemporal dementia with Amyotrophic Lateral Sclerosis by DNA-methylation and GWAS, Sci Rep, 7, 8899, 10.1038/s41598-017-09320-z · DOI
  121. van Olst, 2020, Microglial activation arises after aggregation of phosphorylated-tau in a neuron-specific P301S tauopathy mouse model, Neurobiol Aging, 89, 89, 10.1016/j.neurobiolaging.2020.01.003 · DOI · Paper page
  122. Venneti, 2013, Molecular imaging of microglia/macrophages in the brain, Glia, 61, 10, 10.1002/glia.22357 · DOI · Paper page
  123. Venneti, 2008, The positron emission tomography ligand DAA1106 binds with high affinity to activated microglia in human neurological disorders, J Neuropathol Exp Neurol, 67, 1001, 10.1097/NEN.0b013e318188b204 · DOI · Paper page
  124. Wang, 2015, Role of pro-inflammatory cytokines released from microglia in Alzheimer's disease, Ann Transl Med, 3, 136
  125. Woollacott, 2020, Microglial burden, activation and dystrophy patterns in frontotemporal lobar degeneration, J Neuroinflammation, 17, 234, 10.1186/s12974-020-01907-0 · DOI · Paper page
  126. Wu, 2019, Complement C3 is activated in human AD brain and is required for neurodegeneration in mouse models of amyloidosis and tauopathy, Cell Rep, 28, 2111, 10.1016/j.celrep.2019.07.060 · DOI · Paper page
  127. Xiong, 2011, Clinical comparison of progressive aphasia associated with Alzheimer versus FTD-spectrum pathology, J Neurol Neurosurg Psychiatry, 82, 254, 10.1136/jnnp.2010.209916 · DOI · Paper page
  128. Xu, 2014, Memory deficits correlate with tau and spine pathology in P301S MAPT transgenic mice, Neuropathol Appl Neurobiol, 40, 833, 10.1111/nan.12160 · DOI · Paper page
  129. Yamada, 2014, Neuronal activity regulates extracellular tau in vivo, J Exp Med, 211, 387, 10.1084/jem.20131685 · DOI · Paper page

Cited by

See all 42

Metadata

Authors
Hartnell, I. J., Blum, D., Nicoll, J. A. R., Dorothee, G., & Boche, D.
Affiliations
  • Clinical Neurosciences, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK
  • University of Lille, Inserm, CHU-Lille, UMR-S 1172—Lille Neuroscience and Cognition, Lille, France
  • Inserm, Sorbonne University, UMRS 938 Saint-Antoine Research Center, Immune System and Neuroinflammation Laboratory, Hôpital Saint-Antoine, Paris, France
Venue
Brain
Published
2021-01-26
Volume
144
Issue
3
Pages
724-745
ISSN
  • 0006-8950
  • 1460-2156
Cited by
42
References
100
Language
en
Funders
  • Alzheimer’s Research UK (ARUK-PG2018A-012)
  • ANR (ANR-18-CE16-0008)
  • Network of Centres of Excellence in Neurodegeneration (CoEN 5008)
  • Fondation Plan Alzheimer
  • Fondation pour la Recherche Médicale
  • LECMA/Fondation Vaincre Alzheimer

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.